Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Hospital Authority, Hong Kong GlaxoSmithKline |
---|---|
Information provided by: | Hospital Authority, Hong Kong |
ClinicalTrials.gov Identifier: | NCT00563134 |
Sepsis sometimes occurs in people who have a serious infection. It is caused by toxic substances (toxins) from bacteria and other germs entering your bloodstream. Most people with sepsis will recover with routine medical care before the illness gets more serious. However, in some people, sepsis does become more serious. This severe sepsis can cause damage to internal organs (such as your heart, lungs, kidneys, and liver) and can be life threatening. Special natural fats, (called 'lipoproteins') in our blood are thought to help protect us from the toxins produced by bacteria during sepsis. Levels of these lipoproteins are often low in people with sepsis and this may make it more difficult to recover from the disease. GR270773 is a new drug that has been developed to help the lipoproteins in protecting the body against toxins. GR270773 is made from purified fats and oils from the soyabean and does not contain cholesterol. This research study will test the safety (side effects) of GR270773 and whether or not it is effective in preventing complications in people with severe sepsis.
Condition | Intervention |
---|---|
Gram-Negative Bacterial Infections Sepsis |
Drug: GR270774 |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety Study |
Official Title: | A Prospective, Randomized, Double-Blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-Negative Severe Sepsis in Adults |
Estimated Enrollment: | 1800 |
Study Start Date: | October 2005 |
Estimated Study Completion Date: | December 2006 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Subject has one of the following bacterial infections (as defined in Section 14.5) and a suspected or confirmed Gram-negative etiology:
Subject has signs of new-onset severe sepsis as evidenced by at least ONE of the following hypoperfusion abnormalities OR organ failures caused by the current episode of sepsis. Subject must receive study medication within 12 hours from onset of the first sepsis-related hypoperfusion abnormality or organ failure:
Exclusion Criteria:
Note: Subjects with advanced directives prohibiting only chest compression (CPR) are eligible for the study.
Note: the use of topical amphotericin and oral amphotericin products are permitted and may be administered concomitantly with study drug at the discretion of the investigator.
Study ID Numbers: | KW/FR/04-018, HARECCTR0500030 |
Study First Received: | November 21, 2007 |
Last Updated: | June 23, 2009 |
ClinicalTrials.gov Identifier: | NCT00563134 History of Changes |
Health Authority: | Hong Kong: Ethics Committee |
Suspected or confirmed severe Gram-negative sepsis |
Systemic Inflammatory Response Syndrome Bacterial Infections Sepsis Inflammation Gram-Negative Bacterial Infections |
Systemic Inflammatory Response Syndrome Bacterial Infections Sepsis Pathologic Processes |
Infection Inflammation Gram-Negative Bacterial Infections |